drugset / Trial / NCT00186836

Efficacy Study of Combined Hepatitis A and Hepatitis B Vaccine to Protect Against Hepatitis B in Hemodialysis Patients

NCT00186836 ↗

Phase 4 Completed 200 enrolled St. Joseph's Health Care London
RandomizedParallel-groupSingle-blindPrevention

Summary

Does vaccinating hemodialysis patients with Twinrix® (combination vaccine against hepatitis A and hepatitis B) result in a difference in hepatitis B antibody response in comparison to the monovalent hepatitis B vaccine? Hepatitis B infection is an important cause of mortality and morbidity. Current standard vaccination practices have low efficacy levels in patients (eg. hemodialysis patients) who are most susceptible of infection. Efficacy of the two regiments will be studied.

Timeline

Start
2004-11
Primary completion
—
Completion
2006-11

Outcome

Met primary endpoint

paper Intention-to-treat analysis showed 58% and 38% seroprotection rates in the treatment and control groups, respectively (P = 0.02; RR, 1.5; absolute abatement, 20%). PMID 20630640 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Engerix-B Vaccine 20 ug Intramuscular
Subject Engerix-B Vaccine 40 ug Intramuscular
Subject Twinrix Vaccine 20 ug Intramuscular